242 related articles for article (PubMed ID: 35593080)
1. Altered splicing of ATG16-L1 mediates acquired resistance to tyrosine kinase inhibitors of EGFR by blocking autophagy in non-small cell lung cancer.
Hatat AS; Benoit-Pilven C; Pucciarelli A; de Fraipont F; Lamothe L; Perron P; Rey A; Levra MG; Toffart AC; Auboeuf D; Eymin B; Gazzeri S
Mol Oncol; 2022 Oct; 16(19):3490-3508. PubMed ID: 35593080
[TBL] [Abstract][Full Text] [Related]
2. Curcumin overcome primary gefitinib resistance in non-small-cell lung cancer cells through inducing autophagy-related cell death.
Chen P; Huang HP; Wang Y; Jin J; Long WG; Chen K; Zhao XH; Chen CG; Li J
J Exp Clin Cancer Res; 2019 Jun; 38(1):254. PubMed ID: 31196210
[TBL] [Abstract][Full Text] [Related]
3. Elevated NOX4 promotes tumorigenesis and acquired EGFR-TKIs resistance via enhancing IL-8/PD-L1 signaling in NSCLC.
Liu WJ; Wang L; Zhou FM; Liu SW; Wang W; Zhao EJ; Yao QJ; Li W; Zhao YQ; Shi Z; Qiu JG; Jiang BH
Drug Resist Updat; 2023 Sep; 70():100987. PubMed ID: 37392558
[TBL] [Abstract][Full Text] [Related]
4. EGFR-T790M Mutation-Derived Interactome Rerouted EGFR Translocation Contributing to Gefitinib Resistance in Non-Small Cell Lung Cancer.
Wu PS; Lin MH; Hsiao JC; Lin PY; Pan SH; Chen YJ
Mol Cell Proteomics; 2023 Sep; 22(9):100624. PubMed ID: 37495186
[TBL] [Abstract][Full Text] [Related]
5. The canonical TGF-β/Smad signalling pathway is involved in PD-L1-induced primary resistance to EGFR-TKIs in EGFR-mutant non-small-cell lung cancer.
Zhang Y; Zeng Y; Liu T; Du W; Zhu J; Liu Z; Huang JA
Respir Res; 2019 Jul; 20(1):164. PubMed ID: 31331328
[TBL] [Abstract][Full Text] [Related]
6. ELK1/MTOR/S6K1 Pathway Contributes to Acquired Resistance to Gefitinib in Non-Small Cell Lung Cancer.
Zhao L; Wang Y; Sun X; Zhang X; Simone N; He J
Int J Mol Sci; 2024 Feb; 25(4):. PubMed ID: 38397056
[TBL] [Abstract][Full Text] [Related]
7. The Impact of Inadequate Exposure to Epidermal Growth Factor Receptor-Tyrosine Kinase Inhibitors on the Development of Resistance in Non-Small-Cell Lung Cancer Cells.
Frezzetti D; Caridi V; Marra L; Camerlingo R; D'Alessio A; Russo F; Dotolo S; Rachiglio AM; Esposito Abate R; Gallo M; Maiello MR; Morabito A; Normanno N; De Luca A
Int J Mol Sci; 2024 Apr; 25(9):. PubMed ID: 38732063
[TBL] [Abstract][Full Text] [Related]
8. EZH2 inhibitors reverse resistance to gefitinib in primary EGFR wild-type lung cancer cells.
Gong H; Li Y; Yuan Y; Li W; Zhang H; Zhang Z; Shi R; Liu M; Liu C; Chen C; Liu H; Chen J
BMC Cancer; 2020 Dec; 20(1):1189. PubMed ID: 33276757
[TBL] [Abstract][Full Text] [Related]
9. miR-4487 Enhances Gefitinib-Mediated Ubiquitination and Autophagic Degradation of EGFR in Non-Small Cell Lung Cancer Cells by Targeting USP37.
Kim MS; Kim SH; Yang SH; Kim MS
Cancer Res Treat; 2022 Apr; 54(2):445-457. PubMed ID: 34352998
[TBL] [Abstract][Full Text] [Related]
10. Abnormally activated OPN/integrin αVβ3/FAK signalling is responsible for EGFR-TKI resistance in EGFR mutant non-small-cell lung cancer.
Fu Y; Zhang Y; Lei Z; Liu T; Cai T; Wang A; Du W; Zeng Y; Zhu J; Liu Z; Huang JA
J Hematol Oncol; 2020 Dec; 13(1):169. PubMed ID: 33287873
[TBL] [Abstract][Full Text] [Related]
11. MUSASHI-2 confers resistance to third-generation EGFR-tyrosine kinase inhibitor osimertinib in lung adenocarcinoma.
Yiming R; Takeuchi Y; Nishimura T; Li M; Wang Y; Meguro-Horike M; Kohno T; Horike SI; Nakata A; Gotoh N
Cancer Sci; 2021 Sep; 112(9):3810-3821. PubMed ID: 34145929
[TBL] [Abstract][Full Text] [Related]
12. Activation of the HSP27-AKT axis contributes to gefitinib resistance in non-small cell lung cancer cells independent of EGFR mutations.
Choi SK; Kim M; Lee H; Kwon Y; Cha HJ; Jang SJ; Na Y; Lee YS
Cell Oncol (Dordr); 2022 Oct; 45(5):913-930. PubMed ID: 35931945
[TBL] [Abstract][Full Text] [Related]
13. TRIP13 overexpression promotes gefitinib resistance in non‑small cell lung cancer via regulating autophagy and phosphorylation of the EGFR signaling pathway.
Xiao Z; Li M; Zhang X; Rong X; Xu H
Oncol Rep; 2023 May; 49(5):. PubMed ID: 36896765
[TBL] [Abstract][Full Text] [Related]
14. Epithelial-mesenchymal transition (EMT) beyond EGFR mutations per se is a common mechanism for acquired resistance to EGFR TKI.
Weng CH; Chen LY; Lin YC; Shih JY; Lin YC; Tseng RY; Chiu AC; Yeh YH; Liu C; Lin YT; Fang JM; Chen CC
Oncogene; 2019 Jan; 38(4):455-468. PubMed ID: 30111817
[TBL] [Abstract][Full Text] [Related]
15. Pemetrexed induces ROS generation and cellular senescence by attenuating TS-mediated thymidylate metabolism to reverse gefitinib resistance in NSCLC.
Chen Y; Zhang C; Jin S; Li J; Dai J; Zhang Z; Guo R
J Cell Mol Med; 2023 Jul; 27(14):2032-2044. PubMed ID: 37278440
[TBL] [Abstract][Full Text] [Related]
16. A novel STAT3 inhibitor W2014-S regresses human non-small cell lung cancer xenografts and sensitizes EGFR-TKI acquired resistance.
Zheng Q; Dong H; Mo J; Zhang Y; Huang J; Ouyang S; Shi S; Zhu K; Qu X; Hu W; Liu P; Wang Y; Zhang X
Theranostics; 2021; 11(2):824-840. PubMed ID: 33391507
[TBL] [Abstract][Full Text] [Related]
17. Monitoring the Response of PD-L1 Expression to Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors in Nonsmall-Cell Lung Cancer Xenografts by Immuno-PET Imaging.
Li D; Zou S; Cheng S; Song S; Wang P; Zhu X
Mol Pharm; 2019 Aug; 16(8):3469-3476. PubMed ID: 31283253
[TBL] [Abstract][Full Text] [Related]
18. YM155 sensitizes non-small cell lung cancer cells to EGFR-tyrosine kinase inhibitors through the mechanism of autophagy induction.
Dai CH; Shu Y; Chen P; Wu JN; Zhu LH; Yuan RX; Long WG; Zhu YM; Li J
Biochim Biophys Acta Mol Basis Dis; 2018 Dec; 1864(12):3786-3798. PubMed ID: 30315932
[TBL] [Abstract][Full Text] [Related]
19. Enhanced Sensitivity of Nonsmall Cell Lung Cancer with Acquired Resistance to Epidermal Growth Factor Receptor-Tyrosine Kinase Inhibitors to Phenformin: The Roles of a Metabolic Shift to Oxidative Phosphorylation and Redox Balance.
Kim S; Im JH; Kim WK; Choi YJ; Lee JY; Kim SK; Kim SJ; Kwon SW; Kang KW
Oxid Med Cell Longev; 2021; 2021():5428364. PubMed ID: 34367462
[TBL] [Abstract][Full Text] [Related]
20. Targeting the epidermal growth factor receptor in non-small cell lung cancer cells: the effect of combining RNA interference with tyrosine kinase inhibitors or cetuximab.
Chen G; Kronenberger P; Teugels E; Umelo IA; De Grève J
BMC Med; 2012 Mar; 10():28. PubMed ID: 22436374
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]